Mouse models of insulin resistance and type 2 diabetes

Annales d'Endocrinologie

Volumn 65, Issue 1, 2004, Pages 51-59

  Postic, C ^a   Mauvais Jarvis, F ^a   Girard, J ^a  

^a INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR;

ANIMAL MODEL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETOGENESIS; INSULIN RELEASE; INSULIN RESISTANCE; KNOCKOUT MOUSE; MATURITY ONSET DIABETES MELLITUS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PHENOTYPE; SKELETAL MUSCLE; TISSUE SPECIFICITY; WHITE ADIPOSE TISSUE;

EID: 2342586168     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4266(04)95630-2     Document Type: Conference Paper

References (70)

1. Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001; 409: 729-33.
2. Accili D, Drago J, Iee E, et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 1996; 12: 106-9.
3. Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H. beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev 1998; 12: 1763-8.
4. Bluher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 2003; 299: 572-4.
5. Bluher M, Michael MD, Peroni OD, et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 2002; 3: 25-38.
6. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122-5.
7. Bruning JC, Michael M, Winney J, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998; 2: 559-69.
8. Cariou B, Postic C, Boudou P, et al. Cellular and Molecular Mechanisms of Adipose Tissue Plasticity in Muscle Insulin Receptor Knockout Mice, Endocrinology 2003.
9. Cline GW, Petersen KF, Krssak M, et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999; 341: 240-6.
10. Colombo C, Cutson JJ, Yamauchi T, et al. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 2002; 51: 2727-33.
11. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-68.
12. DeMayo FJ, Tsai SY. Targeted gene regulation and gene ablation. Trends Endocrinol Metab 2001; 12: 348-53.
13. Dukes ID, Sreenan S, Roe MW, et al. Defective pancreatic beta-cell glycolytic signaling in hepatocyte nuclear factor-1alpha-deficient mice. J Biol Chem 1998; 273: 24457-64.
14. Dutta S, Bonner-Weir S, Montminy M, Wright C. Regulatory factor linked to late-onset diabetes? Nature 1998; 392: 560.
15. Fajans SS, Maturity-onset diabetes of the young (MODY). Diab Metab Rev 1989; 5: 579-606.
16. Ferrannini E, Galvan AQ, Gastaldelli A, et al. Insulin: new roles for an ancient hormone. Eur J Clin Invest 1999; 29: 842-52.
17. Ferré T, Pujol A, Riu E, Bosch F, Valera A. Correction of diabetic alterations by glucokinase. Proc Natl Acad Sci USA 1996; 93: 7225-30.
18. Ferre T, Riu E, Bosch F, Valera A. Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. FASEB J 1996; 10: 1213-8.
19. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003; 301: 370-3.
20. Grupe A, Hultgren B, Ryan S, Ma YH, Bauer M, Stewart TA. Transgenic knockouts reveal a critical requirement for pancreatic β cell glucokinase in maintaining glucose homeostasis. Cell 1995; 83: 69-78.
21. Guerre-Millo M. Extending the glucose/fatty acid cycle: a glucose/ adipose tissue cycle. Biochem Soc Trans 2003; 31: 1161-4.
22. Hariharan N, Farrelly D, Hagan D, et al. Expression of human hepatic glucokinase in transgenic mice liver results in decreased glucose levels and reduced body weight. Diabetes 1997; 46: 11-6.
23. Hevener AL, He W, Barak Y, et al. Muscle-specific Pparg deletion causes insulin resistance. Nat Med 2003; 9: 1491-7.
24. Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 1997; 17: 384-355.
25. Hribal ML, Oriente F, Accili D. Mouse models of insulin resistance. Am J Physiol Endocrinol Metab 2002; 282: E977-81.
26. Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 1994; 371: 606-9.
27. Joshi R, Lamothe B, Cordonnier N, et al. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J 1996; 15: 1542-7.
28. Kahn CR. Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes. Experimental Diab Res 2003; 4: 169-82.
29. Kahn RC. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 43: 1066-84.
30. Kido Y, Philippe N, Schaffer AA, Accili D. Genetic modifiers of the insulin resistance phenotype in mice. Diabetes 2000; 49: 589-96.
31. Kitamura T, Kahn CR, Accili D. Insulin receptor knockout mice. Annu Rev Physiol 2003; 65: 313-32.
32. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999; 96: 329-39.
33. Kulkarni RN, Hashimi N, Winnay JN, Curtiss SE, Kahn CR. Impact of the genetic background on insulin receptor and insulin receptor substrate-1 double heterozygous mice, In: Diabetes Mellitus: Molecular Mechanisms, genetics and Prospects for new therapy 2000.
34. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-6.
35. Lewandoski M. Conditional control of gene expression in the mouse. Nat Rev Genet 2001; 2: 743-55.
36. Lin J, Arnold HB, Della-Fera MA, Azain MJ, Hartzell DL, Baile CA. Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochem Biophys Res Commun 2002; 291: 701-6.
37. Lin J, Della-Fera MA, Li C, et al. P27 knockout mice: reduced myostatin in muscle and altered adipogenesis. Biochem Biophys Res Commun 2003; 300: 938-42.
38. Magnuson MA, She P, Shiota M. Gene-altered mice and metabolic flux control. J Biol Chem 2003; 278: 32485-8.
39. Marban SL. Hyperinsulinemia precedes insulin resistance in a transgenic mouse model of type 2 diabetes. Diabetes 1992; 41: 145A.
40. Marban SL, Barr V, Roth J. Hyperinsulinemia in transgenic mice leads to insulin resistance, receptor downregulation and glucose intolerance. Diabetes 1990; 39: 59A.
41. Matschinsky FM. Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes 1990; 39: 647-52.
42. Mauvais-Jarvis F, Virkamaki A, Michael MD, et al. A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes 2000; 49: 2126-34.
43. Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6: 87-97.
44. Minokoshi Y, Kahn CR, Kahn BB. Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis. J Biol Chem 2003; 278: 33609-12.
45. Moitra J, Mason MM, Olive M, et al. Life without white fat: a transgenic mouse. Genes Dev 1998; 12: 3168-3181.
46. Niswender KD, Postic C, Jetton TL, et al. Cell-specific expression and regulation of a glucokinase gene locus transgene. J Biol Chem 1997; 272: 22564-22569.
47. Niswender KD, Shiota M, Postic C, Cherrington AD, Magnuson MA. Effects of increased glucokinase gene copy number on blood glucose homeostasis and hepatic glucose metabolism. J Biol Chem 1997; 272: 22570-22572.
48. Norris AW, Chen L, Fisher SJ, et al. Muscle-specific PPAR-gamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003; 112: 608-18.
49. Offield MF, Jetton TL, Labosky PA, et al. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 1996; 122: 983-995.
50. Otani K, Kulkarni RN, Baldwin AC, et al. Reduced {beta}-cell mass and altered glucose sensing impair insulin-secretory function in {beta} IRKO mice. Am J Physiol Endocrinol Metab 2004; 286: E41-E49.
51. Parrizas M, Maestro MA, Boj SF, et al. Hepatic nuclear factor 1-alpha directs nucleosomal hyperacetylation to its tissue-specific transcriptional targets, Mol Cell Biol 2001; 21: 3234-43.
52. Pontoglio M, Sreenan S, Roe M, et al. Defective insulin secretion in hepatocyte nuclear factor 1-alpha-deficient mice. J Clin Invest 1998; 101: 2215-2222.
53. Postic C, Shiota M, Magnuson MA. Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog Horm Res 2001; 56: 195-217.
54. Postic C, Shiota M, Niswender KD, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic β cell specific gene knock-outs using cre recombinase. J Biol Chem 1999; 274: 305-315.
55. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-76.
56. Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998; 12: 3182-3194.
57. Shiota M, Postic C, Fujimoto Y, et al. Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. Diabetes 2001; 50: 622-629.
58. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997; 17: 138-139.
59. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997; 15: 106-110.
60. Terauchi Y, Sakura H, Yasuda K, et al. Pancreatic b-cell specific targeted disruption of glucokinase gene. J Biol Chem 1995; 270: 30253-30256.
61. Thorell A, Hirshman MF, Nygren J, et al. Exercise and insulin cause GLUT-4 translocation in human skeletal muscle. Am J Physiol 1999; 277: E733-41.
62. Trinh KY, O'Doherty RM, Anderson P, Lange AJ, Newgard CB. Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. J Biol Chem 1998; 273: 31615-31620.
63. Valera A, Pujol A, Pelegrin M, Bosch F. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1994; 91: 9151-9154.
64. Vionnet N, Stoffel M, Takeda J, et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 1992; 356: 721-2.
65. Wang H, Antinozzi PA, Hagenfeldt KA, Maechler P, Wollheim CB. Molecular targets of a human HNF1 alpha mutation responsible for pancreatic beta-cell dysfunction. Embo J 2000; 19: 4257-64.
66. Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 2003; 206: 2049-57.
67. Wojtaszewski JF, Higaki Y, Hirshman MF, et al. Exercise modulates postreceptor insulin signaling and glucose transport in muscle-specific insulin receptor knockout mice. J Clin Invest 1999; 104: 1257-1264.
68. Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 1996; 384: 458-60.
69. Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996; 384: 455-458.
70. Zisman A, Peroni OD, Abel ED, et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 2000; 6: 924-928.